139 Pathways

• FCERI mediated MAPK activation,
• APC/C:Cdc20 mediated degradation of Cyclin B,
• MASTL Facilitates Mitotic Progression,
• Double-Strand Break Repair,
• Mitotic Prometaphase,
• Cell Cycle, Mitotic,
• Toll Like Receptor 9 (TLR9) Cascade,
• M/G1 Transition,
• G0 and Early G1,
• Regulation of DNA replication,
• MyD88:Mal cascade initiated on plasma membrane,
• Toll Like Receptor 7/8 (TLR7/8) Cascade,
• Frs2-mediated activation,
• Mitotic Spindle Checkpoint,
• IRS-mediated signalling,
• Toll Like Receptor 10 (TLR10) Cascade,
• G2/M DNA damage checkpoint,
• Activated TLR4 signalling,
• TRAF6 Mediated Induction of proinflammatory cytokines,
• Interleukin-2 signaling,
• Insulin receptor mediated signaling,
• S Phase,
• Toll Like Receptor 3 (TLR3) Cascade,
• NCAM signaling for neurite out-growth,
• IRS-related events triggered by IGF1R,
• Prolonged ERK activation events,
• Signalling to RAS,
• MAP kinase activation in TLR cascade,
• M Phase,
• DINR-mediated activation,
• Mitotic G2-G2/M phases,
• Signaling by FGFR in disease,
• Insulin receptor signalling cascade,
• Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components,
• Homologous recombination repair of replication-independent double-strand breaks,
• Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins,
• Signaling by PDGF,
• Signaling by ERBB4,
• APC/C:Cdc20 mediated degradation of mitotic proteins,
• Regulation of PLK1 Activity at G2/M Transition,
• Cyclin A/B1 associated events during G2/M transition,
• G1/S Transition,
• Gastrin-CREB signalling pathway via PKC and MAPK,
• Immune System,
• SHC1 events in ERBB2 signaling,
• Toll Like Receptor 4 (TLR4) Cascade,
• Ubiquitin Mediated Degradation of Phosphorylated Cdc25A,
• DAP12 interactions,
• G2/M Checkpoints,
• G2/M Transition,
• Amplification of signal from the kinetochores,
• Fc epsilon receptor (FCERI) signaling,
• Signaling by ERBB2,
• Mitotic M-M/G1 phases,
• IGF1R signaling cascade,
• Downstream signaling of activated FGFR,
• Insulin receptor recycling,
• Cell Cycle,
• Phosphorylation of the APC/C,
• Signalling to ERKs,
• SOS-mediated signalling,
• Toll Like Receptor 2 (TLR2) Cascade,
• Axon guidance,
• Resolution of Sister Chromatid Cohesion,
• SHC-related events triggered by IGF1R,
• Toll Like Receptor TLR6:TLR2 Cascade,
• SHC-related events,
• Cyclin A:Cdk2-associated events at S phase entry,
• FRS2-mediated cascade,
• DNA Replication,
• DNA Replication Pre-Initiation,
• Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),
• Toll-Like Receptors Cascades,
• Activation of NIMA Kinases NEK9, NEK6, NEK7,
• G1/S-Specific Transcription,
• Signaling by SCF-KIT,
• G1/S DNA Damage Checkpoints,
• Insulin signaling pathway,
• Assembly of the pre-replicative complex,
• Innate Immune System,
• SHC1 events in ERBB4 signaling,
• DNA Repair,
• Mitotic G1-G1/S phases,
• Nuclear Pore Complex (NPC) Disassembly,
• MyD88 cascade initiated on plasma membrane,
• G2/M DNA replication checkpoint,
• Signaling by EGFR,
• NGF signalling via TRKA from the plasma membrane,
• Cdc20:Phospho-APC/C mediated degradation of Cyclin A,
• E2F mediated regulation of DNA replication,
• Signaling by NGF,
• Cytokine Signaling in Immune system,
• Homologous Recombination Repair,
• p53-Independent G1/S DNA damage checkpoint,
• Toll Like Receptor 5 (TLR5) Cascade,
• Assembly of the ORC complex at the origin of replication,
• Developmental Biology,
• E2F-enabled inhibition of pre-replication complex formation,
• Cyclin B2 mediated events,
• MyD88-independent cascade,
• p53-Independent DNA Damage Response,
• Association of licensing factors with the pre-replicative complex,
• Signalling to p38 via RIT and RIN,
• Downstream signal transduction,
• DAP12 signaling,
• SHC-mediated signalling,
• Toll Like Receptor TLR1:TLR2 Cascade,
• Mitotic Prophase,
• Nuclear Envelope Breakdown,
• Signaling by GPCR,
• TRIF-mediated TLR3/TLR4 signaling,
• Regulation of APC/C activators between G1/S and early anaphase,
• ATM mediated response to DNA double-strand break,
• Signaling by FGFR,
• Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex,
• RAF/MAP kinase cascade,
• ERK activation,
• Polo-like kinase mediated events,
• Inactivation of APC/C via direct inhibition of the APC/C complex,
• APC/C-mediated degradation of cell cycle proteins,
• Signaling by EGFR in Cancer,
• Condensation of Prometaphase Chromosomes,
• ARMS-mediated activation,
• ERK1 activation,
• SCF-beta-TrCP mediated degradation of Emi1,
• SHC1 events in EGFR signaling,
• Signaling by Interleukins,
• Signaling Pathways,
• Signaling by Leptin,
• GRB2 events in ERBB2 signaling,
• MyD88 dependent cascade initiated on endosome,
• Disease,
• Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal,
• IRS-related events,
• TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,
• GRB2 events in EGFR signaling,
• Cell Cycle Checkpoints,
• Cyclin E associated events during G1/S transition,
• Regulation of mitotic cell cycle